Infertility
Conditions
Keywords
Assisted reproductive treatment, GnRH antagonist, Estrogen pre-treatment, Ovarian stimulation
Brief summary
The purpose of this study is to assess whether estrogen pre-treatment can allow retrieval of 2 additional oocytes in GnRH antagonist protocol.
Interventions
DRUG17beta-estradiol
Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
Sponsors
Gemer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 38 Years
Healthy volunteers
No
Inclusion criteria
* regular normo-ovulatory cycles (28 to 35 days) * age \< 38 years, * body mass index (BMI) between 18 and 30 * first or second IVF/ICSI attempt
Exclusion criteria
* high basal levels of serum FSH or E2, * less than 5 follicles at the antral follicular count performed on day 3 of a spontaneous cycle, * history of high (\>20 oocytes) or low (\< 5 oocytes) ovarian response in a previous IVF attempt
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number of retrieved oocytes | at the ovarian puncture, 36 hours post HCG administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| pregnancy rate | at pregnancy test and at 6 Week US examination | — |
| delivery rate | 9 months later | — |
| number of obtained embryos | 2 days after in vitro fertilization | — |
| duration of FSH administration | at the end of ovarian stimulation usually after a mean of 12 days of administration | number of days of administration |
| Total FSH dose | at the end of ovarian stimulation usually after a mean of 12 days of administration | daily dose x number of days of administration |
Countries
France
Outcome results
None listed